东阳光药业:抗感染单品贡献超八成收入,终止丙型肝炎项目或减值上亿元

金证研
Yesterday

文|《金证研》 轶洺2025年3月28日,港股上市公司宜昌东阳光长江药业股份有限公司(简称“东阳光长江药业”)发布其2024年业绩公告,全年营业额达37.24亿元,股东应占溢利4.83亿元。而此前,广东东阳光药业股份有限公司(简称“东阳光药业”)与东阳光长江药业发布联合声明,东阳光药业拟吸收合并东阳光长江药业,并以介绍方式在港上市。冲击港股上市背后,东阳光药业在2023年扭亏为盈,近三年一期,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10